CTOs on the Move

Synageva BioPharma

www.synageva.com

 
Synageva BioPharma Corp. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.synageva.com
  • 128 Spring St Ste 520
    Lexington, MA USA 02421
  • Phone: 781.357.9900

Executives

Name Title Contact Details

Similar Companies

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.

PT Development LLC.

PT Development (PTD) is a Louisville-based operational management firm that specializes in providing operational efficiencies such as accounting, customer service, marketing, compliance, and human resource services to privately held physical therapy practices.   Founded by Dr. Larry Benz in 1994, PTD’s primary goal is to help our clients achieve clinical excellence through aligning business strategies, streamlining processes, and building equity through quality customer service.

DuPont Pioneer

DuPont Pioneer headquartered in Des Moines, Iowa, is the world’s leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. DuPont Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere. Science with Service Delivering Success.

Hygiena

Hygiena is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Volastra Therapeutics

Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.